Current advances in T-cell-based cancer immunotherapy

Immunotherapy

Volumn 6, Issue 12, 2014, Pages 1265-1278

  Wang, Mingjun ^a   Yin, Bingnan ^a   Wang, Helen Y ^a   Wang, Rong Fu ^a  

^a HOUSTON METHODIST RESEARCH INSTITUTE   (United States)

Author keywords

adoptive cell transfer; cancer antigen specific T cells; cancer immunotherapy; genetically modified T cells

Indexed keywords

BIOLOGICAL MARKER; T LYMPHOCYTE RECEPTOR; TUMOR ANTIGEN;

ADOPTIVE TRANSFER; ANTIGEN SPECIFICITY; CANCER IMMUNOTHERAPY; CANCER PATIENT; CANCER STAGING; CANCER SURVIVAL; HUMAN; REVIEW; T LYMPHOCYTE; ADOPTIVE IMMUNOTHERAPY; ANIMAL; DRUG RESISTANCE; IMMUNOLOGY; NEOPLASMS; TRANSPLANTATION; TRENDS;

ADOPTIVE TRANSFER; ANIMALS; DRUG RESISTANCE, NEOPLASM; HUMANS; IMMUNOTHERAPY, ADOPTIVE; NEOPLASM STAGING; NEOPLASMS; T-LYMPHOCYTES;

EID: 84919789714     PISSN: 1750743X     EISSN: 17507448     Source Type: Journal    
DOI: 10.2217/imt.14.86     Document Type: Review

References (114)

1. Jemal A, Bray F, Center MM, Ferlay J, Ward E, Forman D. Global cancer statistics. CA Cancer J. Clin. 61(2), 69-90 (2011).
2. Wagner PD, Srivastava S. New paradigms in translational science research in cancer biomarkers. Transl. Res. 159(4), 343-353 (2012).
3. Kochenderfer JN, Rosenberg SA. Treating B-cell cancer with T cells expressing anti-CD19 chimeric antigen receptors. Nat. Rev. Clin. Oncol. 10(5), 267-276 (2013).
4. Restifo NP, Dudley ME, Rosenberg SA. Adoptive immunotherapy for cancer: harnessing the Tcell response. Nat. Rev. Immunol. 12(4), 269-281 (2012).
5. Sharma P, Wagner K, Wolchok JD, Allison JP. Novel cancer immunotherapy agents with survival benefit: recent successes and next steps. Nat. Rev. Cancer 11(11), 805-812 (2011).
6. Mellman I, Coukos G, Dranoff G. Cancer immunotherapy comes of age. Nature 480(7378), 480-489 (2011).
7. Kantoff PW, Higano CS, Shore ND et al. Sipuleucel-T immunotherapy for castration-resistant prostate cancer. N. Engl. J. Med. 363(5), 411-422 (2010).
8. Hodi FS, O'Day SJ, Mcdermott DF et al. Improved survival with ipilimumab in patients with metastatic melanoma. N. Engl. J. Med. 363(8), 711-723 (2010).
9. Schwartzentruber DJ, Lawson DH, Richards JM et al. gp100 peptide vaccine and interleukin-2 in patients with advanced melanoma. N. Engl. J. Med. 364(22), 2119-2127 (2011).
10. Ruella M, Kalos M. Adoptive immunotherapy for cancer. Immunol. Rev. 257(1), 14-38 (2014).
11. Jensen MC, Riddell SR. Design and implementation of adoptive therapy with chimeric antigen receptor-modified T cells. Immunol. Rev. 257(1), 127-144 (2014).
12. Hinrichs CS, Rosenberg SA. Exploiting the curative potential of adoptive T-cell therapy for cancer. Immunol. Rev. 257(1), 56-71 (2014).
13. Dotti G, Gottschalk S, Savoldo B, Brenner MK. Design and development of therapies using chimeric antigen receptor-expressing Tcells. Immunol. Rev. 257(1), 107-126 (2014).
14. Cheadle EJ, Gornall H, Baldan V, Hanson V, Hawkins RE, Gilham DE. CAR Tcells: driving the road from the laboratory to the clinic. Immunol. Rev. 257(1), 91-106 (2014).
15. Rosenberg SA, Packard BS, Aebersold PM et al. Use of tumor-infiltrating lymphocytes and interleukin-2 in the immunotherapy of patients with metastatic melanoma. A preliminary report. N. Engl. J. Med. 319(25), 1676-1680 (1988).
16. Rosenberg SA, Yang JC, Sherry RM et al. Durable complete responses in heavily pretreated patients with metastatic melanoma using T-cell transfer immunotherapy. Clin. Cancer Res. 17(13), 4550-4557 (2011).
17. Couzin-Frankel J. Breakthrough of the year 2013. Cancer immunotherapy. Science 342(6165), 1432-1433 (2013).
18. Vesely MD, Kershaw MH, Schreiber RD, Smyth MJ. Natural innate and adaptive immunity to cancer. Annu. Rev. Immunol. 29, 235-271 (2011).
19. Schreiber RD, Old LJ, Smyth MJ. Cancer immunoediting: integrating immunity's roles in cancer suppression and promotion. Science 331(6024), 1565-1570 (2011).
20. Rosenberg SA. Cell transfer immunotherapy for metastatic solid cancer - what clinicians need to know. Nat. Rev. Clin. Oncol. 8(10), 577-585 (2011).
21. Wang HY, Wang RF. Enhancing cancer immunotherapy by intracellular delivery of cell-penetrating peptides and stimulation of pattern-recognition receptor signaling. Adv. Immunol. 114, 151-176 (2012).
22. Van Den Eynde B, Lethe B, Van Pel A, De Plaen E, Boon T. The gene coding for a major tumor rejection antigen of tumor P815 is identical to the normal gene of syngeneic DBA/2 mice. J. Exp. Med. 173(6), 1373-1384 (1991).
23. Vigneron N, Stroobant V, Van Den Eynde BJ, Van Der Bruggen P. Database of Tcell-defined human tumor antigens: the 2013 update. Cancer Immun. 13, 15 (2013).
24. Cancer Immunity: Peptide Database.www.cancerimmunity.org/peptide
25. +) Tcells for cancer immunotherapy. PLoS ONE 7(9), e45756 (2012).
26. + T-cell response to mitochondrial cytochrome B in human melanoma. Cancer Res. 66(11), 5919-5926 (2006).
27. +) Tcells: implication for cancer immunotherapy. PLoS ONE 8(2), e56730 (2013).
28. Wang RF. Enhancing antitumor immune responses: intracellular peptide delivery and identification of MHC class II-restricted tumor antigens. Immunol. Rev. 188, 65-80 (2002).
29. Wang RF, Appella E, Kawakami Y, Kang X, Rosenberg SA. Identification of TRP-2 as a human tumor antigen recognized by cytotoxic T lymphocytes. J. Exp. Med. 184(6), 2207-2216 (1996).
30. Wang RF, Johnston SL, Southwood S, Sette A, Rosenberg SA. Recognition of an antigenic peptide derived from tyrosinase-related protein-2 by CTL in the context of HLA-A31 and -A33. J. Immunol. 160(2), 890-897 (1998).
31. Wang RF, Johnston SL, Zeng G, Topalian SL, Schwartzentruber DJ, Rosenberg SA. A breast and melanoma-shared tumor antigen: Tcell responses to antigenic peptides translated from different open reading frames. J. Immunol. 161(7), 3598-3606 (1998).
32. Wang RF, Parkhurst MR, Kawakami Y, Robbins PF, Rosenberg SA. Utilization of an alternative open reading frame of a normal gene in generating a novel human cancer antigen. J. Exp. Med. 183(3), 1131-1140 (1996).
33. Wang RF, Robbins PF, Kawakami Y, Kang XQ, Rosenberg SA. Identification of a gene encoding a melanoma tumor antigen recognized by HLA-A31-restricted tumor-infiltrating lymphocytes. J. Exp. Med. 181(2), 799-804 (1995).
34. Wang RF, Rosenberg SA. Human tumor antigens for cancer vaccine development. Immunol. Rev. 170, 85-100 (1999).
35. Peng W, Wang HY, Miyahara Y, Peng G, Wang RF. Tumor-associated galectin-3 modulates the function of tumor-reactive T cells. Cancer Res. 68(17), 7228-7236 (2008).
36. + T cells in antitumor immunity. Trends Immunol. 22(5), 269-276 (2001).
37. Wang RF, Wang X, Atwood AC, Topalian SL, Rosenberg SA. Cloning genes encoding MHC class II-restricted antigens: mutated CDC27 as a tumor antigen. Science 284(5418), 1351-1354 (1999).
38. +) Tcells. J. Exp. Med. 189(10), 1659-1668 (1999).
39. Palucka K, Banchereau J. Cancer immunotherapy via dendritic cells. Nat. Rev. Cancer 12(4), 265-277 (2012).
40. Chen L, Flies DB. Molecular mechanisms of Tcell co-stimulation and co-inhibition. Nat. Rev. Immunol. 13(4), 227-242 (2013).
41. Topalian SL, Hodi FS, Brahmer JR et al. Safety, activity, and immune correlates of anti-PD-1 antibody in cancer. N. Engl. J. Med. 366(26), 2443-2454 (2012).
42. Brahmer JR, Tykodi SS, Chow LQ et al. Safety and activity of anti-PD-L1 antibody in patients with advanced cancer. N. Engl. J. Med. 366(26), 2455-2465 (2012).
43. Royal RE, Levy C, Turner K et al. Phase2 trial of single agent Ipilimumab (anti-CTLA-4) for locally advanced or metastatic pancreatic adenocarcinoma. J. Immunother. 33(8), 828-833 (2010).
44. Shevach EM. Application of IL-2 therapy to target T regulatory cell function. Trends Immunol. 33(12), 626-632 (2012).
45. Wang HY, Wang RF. Regulatory Tcells and cancer. Curr. Opin. Immunol. 19(2), 217-223 (2007).
46. + regulatory Tcells in the human immune system. Nat. Rev. Immunol. 10(7), 490-500 (2010).
47. Peng G, Wang HY, Peng W, Kiniwa Y, Seo KH, Wang RF. Tumor-infiltrating gammadelta Tcells suppress T and dendritic cell function via mechanisms controlled by a unique toll-like receptor signaling pathway. Immunity 27(2), 334-348 (2007).
48. + regulatory Tcell function. Science 309(5739), 1380-1384 (2005).
49. Robert C, Thomas L, Bondarenko I et al. Ipilimumab plus dacarbazine for previously untreated metastatic melanoma. N. Engl. J. Med. 364(26), 2517-2526 (2011).
50. Yee C. The use of endogenous Tcells for adoptive transfer. Immunol. Rev. 257(1), 250-263 (2014).
51. Dudley ME, Wunderlich JR, Robbins PF et al. Cancer regression and autoimmunity in patients after clonal repopulation with antitumor lymphocytes. Science 298(5594), 850-854 (2002).
52. + T cell clones for the treatment of patients with metastatic melanoma: invivo persistence, migration, and antitumor effect of transferred Tcells. Proc. Natl Acad. Sci. USA 99(25), 16168-16173 (2002).
53. + T cells for the treatment of patients with metastatic melanoma. J. Clin. Oncol. 24(31), 5060-5069 (2006).
54. + T cells agaInst. NY-ESO-1. N. Engl. J. Med. 358(25), 2698-2703 (2008).
55. Khammari A, Labarriere N, Vignard V et al. Treatment of metastatic melanoma with autologous Melan-A/MART-1-specific cytotoxic T lymphocyte clones. J. Invest. Dermatol. 129(12), 2835-2842 (2009).
56. + T cells persist, mediate tumor regression, and acquire central memory phenotype. Proc. Natl Acad. Sci. USA 109(12), 4592-4597 (2012).
57. Morgan RA, Dudley ME, Wunderlich JR et al. Cancer regression in patients after transfer of genetically engineered lymphocytes. Science 314(5796), 126-129 (2006).
58. Johnson LA, Morgan RA, Dudley ME et al. Gene therapy with human and mouse T-cell receptors mediates cancer regression and targets normal tissues expressing cognate antigen. Blood 114(3), 535-546 (2009).
59. Parkhurst MR, Yang JC, Langan RC et al. T cells targeting carcinoembryonic antigen can mediate regression of metastatic colorectal cancer but induce severe transient colitis. Mol. Ther. 19(3), 620-626 (2011).
60. Robbins PF, Morgan RA, Feldman SA et al. Tumor regression in patients with metastatic synovial cell sarcoma and melanoma using genetically engineered lymphocytes reactive with NY-ESO-1. J. Clin. Oncol. 29(7), 917-924 (2011).
61. Morgan RA, Chinnasamy N, Abate-Daga D et al. Cancer regression and neurological toxicity following anti-MAGE-A3 TCR gene therapy. J. Immunother. 36(2), 133-151 (2013).
62. Cameron BJ, Gerry AB, Dukes J et al. Identification of a Titin-derived HLA-A1-presented peptide as a cross-reactive target for engineered MAGE A3-directed Tcells. Sci. Transl. Med. 5(197), 197ra103 (2013).
63. Linette GP, Stadtmauer EA, Maus MV et al. Cardiovascular toxicity and titin cross-reactivity of affinity-enhanced Tcells in myeloma and melanoma. Blood 122(6), 863-871 (2013).
64. Louis CU, Savoldo B, Dotti G et al. Antitumor activity and long-term fate of chimeric antigen receptor-positive Tcells in patients with neuroblastoma. Blood 118(23), 6050-6056 (2011).
65. Lamers CH, Sleijfer S, Van Steenbergen S et al. Treatment of metastatic renal cell carcinoma with CAIX CAR-engineered T cells: clinical evaluation and management of on-target toxicity. Mol. Ther. 21(4), 904-912 (2013).
66. Morgan RA, Yang JC, Kitano M, Dudley ME, Laurencot CM, Rosenberg SA. Case report of a serious adverse event following the administration of Tcells transduced with a chimeric antigen receptor recognizing ERBB2. Mol. Ther. 18(4), 843-851 (2010).
67. Kochenderfer JN, Wilson WH, Janik JE et al. Eradication of B-lineage cells and regression of lymphoma in a patient treated with autologous Tcells genetically engineered to recognize CD19. Blood 116(20), 4099-4102 (2010).
68. Kochenderfer JN, Dudley ME, Feldman SA et al. B-cell depletion and remissions of malignancy along with cytokine-associated toxicity in a clinical trial of anti-CD19 chimeric-antigen-receptor-transduced Tcells. Blood 119(12), 2709-2720 (2012).
69. Porter DL, Levine BL, Kalos M, Bagg A, June CH. Chimeric antigen receptor-modified Tcells in chronic lymphoid leukemia. N. Engl. J. Med. 365(8), 725-733 (2011).
70. Kalos M, Levine BL, Porter DL et al. T cells with chimeric antigen receptors have potent antitumor effects and can establish memory in patients with advanced leukemia. Sci. Transl. Med. 3(95), 95ra73 (2011).
71. Grupp SA, Kalos M, Barrett D et al. Chimeric antigen receptor-modified Tcells for acute lymphoid leukemia. N. Engl. J. Med. 368(16), 1509-1518 (2013).
72. Brentjens RJ, Davila ML, Riviere I et al. CD19-targeted T cells rapidly induce molecular remissions in adults with chemotherapy-refractory acute lymphoblastic leukemia. Sci. Transl. Med. 5(177), 177ra138 (2013).
73. Davila ML, Riviere I, Wang X et al. Efficacy and toxicity management of 19-28z CAR Tcell therapy in B cell acute lymphoblastic leukemia. Sci. Transl. Med. 6(224), 224ra225 (2014).
74. Grimm EA, Mazumder A, Zhang HZ, Rosenberg SA. Lymphokine-activated killer cell phenomenon. Lysis of natural killer-resistant fresh solid tumor cells by interleukin 2-activated autologous human peripheral blood lymphocytes. J. Exp. Med. 155(6), 1823-1841 (1982).
75. Schmidt-Wolf IG, Negrin RS, Kiem HP, Blume KG, Weissman IL. Use of a SCID mouse/human lymphoma model to evaluate cytokine-induced killer cells with potent antitumor cell activity. J. Exp. Med. 174(1), 139-149 (1991).
76. Rosenberg SA, Lotze MT, Muul LM et al. A progress report on the treatment of 157 patients with advanced cancer using lymphokine-activated killer cells and interleukin-2 or high-dose interleukin-2 alone. N. Engl. J. Med. 316(15), 889-897 (1987).
77. Hontscha C, Borck Y, Zhou H, Messmer D, Schmidt-Wolf IG. Clinical trials on CIK cells: first report of the international registry on CIK cells (IRCC). J. Cancer Res. Clin. Oncol. 137(2), 305-310 (2011).
78. Rosenberg SA, Yannelli JR, Yang JC et al. Treatment of patients with metastatic melanoma with autologous tumor-infiltrating lymphocytes and interleukin 2. J. Natl Cancer Inst. 86(15), 1159-1166 (1994).
79. Rosenberg SA, Spiess P, Lafreniere R. A new approach to the adoptive immunotherapy of cancer with tumor-infiltrating lymphocytes. Science 233(4770), 1318-1321 (1986).
80. Robbins PF, Lu YC, El-Gamil M et al. Mining exomic sequencing data to identify mutated antigens recognized by adoptively transferred tumor-reactive Tcells. Nat. Med. 19(6), 747-752 (2013).
81. + T cells in a patient with epithelial cancer. Science 344, 641-645 (2014).
82. Dudley ME, Yang JC, Sherry R et al. Adoptive cell therapy for patients with metastatic melanoma: evaluation of intensive myeloablative chemoradiation preparative regimens. J. Clin. Oncol. 26(32), 5233-5239 (2008).
83. Paulos CM, Wrzesinski C, Kaiser A et al. Microbial translocation augments the function of adoptively transferred self/tumor-specific CD8+ T cells via TLR4 signaling. J. Clin. Invest. 117(8), 2197-2204 (2007).
84. Lee PP, Yee C, Savage PA et al. Characterization of circulating Tcells specific for tumor-associated antigens in melanoma patients. Nat. Med. 5(6), 677-685 (1999).
85. +) Tcells in a large proportion of human histocompatibility leukocyte antigen (HLA)-A2 individuals. J. Exp. Med. 190(5), 705-715 (1999).
86. Sonpavde G, Wang M, Peterson LE et al. HLA-restricted NY-ESO-1 peptide immunotherapy for metastatic castration resistant prostate cancer. Invest. New Drugs 32(2), 235-242 (2014).
87. Yee C, Thompson JA, Roche P et al. Melanocyte destruction after antigen-specific immunotherapy of melanoma: direct evidence of t cell-mediated vitiligo. J. Exp. Med. 192(11), 1637-1644 (2000).
88. Yang S, Ji Y, Gattinoni L et al. Modulating the differentiation status of ex vivo-cultured anti-tumor Tcells using cytokine cocktails. Cancer Immunol. Immunother. 62(4), 727-736 (2013).
89. + T cells responding to antigen without requiring knowledge of epitope specificities. Blood 110(1), 201-210 (2007).
90. Ye Q, Song DG, Poussin M et al. CD137 accurately identifies and enriches for naturally occurring tumor-reactive Tcells in tumor. Clin. Cancer Res. 20(1), 44-55 (2014).
91. Oates J, Jakobsen BK. ImmTACs: novel bi-specific agents for targeted cancer therapy. Oncoimmunology 2(2), e22891 (2013).
92. Mccormack E, Adams KJ, Hassan NJ et al. Bi-specific TCR-anti CD3 redirected T-cell targeting of NY-ESO-1- and LAGE-1-positive tumors. Cancer Immunol. Immunother. 62(4), 773-785 (2013).
93. Liddy N, Bossi G, Adams KJ et al. Monoclonal TCR-redirected tumor cell killing. Nat. Med. 18(6), 980-987 (2012).
94. Gross G, Waks T, Eshhar Z. Expression of immunoglobulin-T-cell receptor chimeric molecules as functional receptors with antibody-type specificity. Proc. Natl Acad. Sci. USA 86(24), 10024-10028 (1989).
95. Chmielewski M, Hombach AA, Abken H. Of CARs and TRUCKs: chimeric antigen receptor (CAR) Tcells engineered with an inducible cytokine to modulate the tumor stroma. Immunol. Rev. 257(1), 83-90 (2014).
96. Chmielewski M, Kopecky C, Hombach AA, Abken H. IL-12 release by engineered Tcells expressing chimeric antigen receptors can effectively Muster an antigen-independent macrophage response on tumor cells that have shut down tumor antigen expression. Cancer Res. 71(17), 5697-5706 (2011).
97. Pegram HJ, Lee JC, Hayman EG et al. Tumor-targeted T cells modified to secrete IL-12 eradicate systemic tumors without need for prior conditioning. Blood 119(18), 4133-4141 (2012).
98. John LB, Devaud C, Duong CP et al. Anti-PD-1 antibody therapy potently enhances the eradication of established tumors by gene-modified Tcells. Clin. Cancer Res. 19(20), 5636-5646 (2013).
99. Peng W, Liu C, Xu C et al. PD-1 blockade enhances T-cell migration to tumors by elevating IFN-gamma inducible chemokines. Cancer Res. 72(20), 5209-5218 (2012).
100. Fedorov VD, Sadelain M, Kloss CC. Novel approaches to enhance the specificity and safety of engineered Tcells. Cancer J. 20(2), 160-165 (2014).
101. Kloss CC, Condomines M, Cartellieri M, Bachmann M, Sadelain M. Combinatorial antigen recognition with balanced signaling promotes selective tumor eradication by engineered Tcells. Nat. Biotechnol. 31(1), 71-75 (2013).
102. Fedorov VD, Themeli M, Sadelain M. PD-1- and CTLA-4-based inhibitory chimeric antigen receptors (iCARs) divert off-target immunotherapy responses. Sci. Transl. Med. 5(215), 215ra172 (2013).
103. Lupo-Stanghellini MT, Provasi E, Bondanza A, Ciceri F, Bordignon C, Bonini C. Clinical impact of suicide gene therapy in allogeneic hematopoietic stem cell transplantation. Hum. Gene Ther. 21(3), 241-250 (2010).
104. Di Stasi A, Tey SK, Dotti G et al. Inducible apoptosis as a safety switch for adoptive cell therapy. N. Engl. J. Med. 365(18), 1673-1683 (2011).
105. Morgan RA. Live and let die: a new suicide gene therapy moves to the clinic. Mol. Ther. 20(1), 11-13 (2012).
106. Gattinoni L, Lugli E, Ji Y et al. A human memory Tcell subset with stem cell-like properties. Nat. Med. 17(10), 1290-1297 (2011).
107. + T cells derived from naive rather than memory subsets possess superior traits for adoptive immunotherapy. Blood 117(3), 808-814 (2011).
108. Zhou P, Shaffer DR, Alvarez Arias DA etal. In vivo discovery of immunotherapy targets in the tumour microenvironment. Nature 506(7486), 52-57 (2014).
109. +) Tcells. Cell Stem Cell 12(1), 31-36 (2013).
110. Nishimura T, Kaneko S, Kawana-Tachikawa A et al. Generation of rejuvenated antigen-specific Tcells by reprogramming to pluripotency and redifferentiation. Cell Stem Cell 12(1), 114-126 (2013).
111. Kalos M. Biomarkers in Tcell therapy clinical trials. J. Transl. Med. 9, 138-146 (2011).
112. Cui J, Li Y, Zhu L et al. NLRP4 negatively regulates type I interferon signaling by targeting the kinase TBK1 for degradation via the ubiquitin ligase DTX4. Nat. Immunol. 13(4), 387-395 (2012).
113. Xia X, Cui J, Wang HY et al. NLRX1 negatively regulates TLR-induced NF-kappaB signaling by targeting TRAF6 and IKK. Immunity 34(6), 843-853 (2011).
114. Cui J, Zhu L, Xia X et al. NLRC5 negatively regulates the NF-kappaB and type I interferon signaling pathways. Cell 141(3), 483-496 (2010).